Takeda Pharmaceutical Co Ltd (TKPHF) stock

TKPHFOTCPharmaceutical PreparationsAlso trades as TAK

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 17, 2026Score 5/30

$39.00+0.36 (+0.93%)

Close on Oct 19, 2026Market cap $134.41BP/E –Yield –

Takeda Pharmaceutical gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2026 it was 65.1%, against 65.5% the year before. The highest annual figure on record is 72.0% in fiscal 2018.

Period	Period end	Value	Change (pts)
FY2026	Mar 31, 2026	65.1%	−0.4
FY2025	Mar 31, 2025	65.5%	−1.0
FY2024	Mar 31, 2024	66.5%	−2.6
FY2023	Mar 31, 2023	69.1%	+0.1
FY2022	Mar 31, 2022	69.0%	+0.1
FY2021	Mar 31, 2021	68.9%	+2.0
FY2020	Mar 31, 2020	66.9%	−2.0
FY2019	Mar 31, 2019	68.9%	−3.1
FY2018	Mar 31, 2018	72.0%	+4.2
FY2017	Mar 31, 2017	67.7%	–

Parsed from the XBRL in Takeda Pharmaceutical's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TKPHF.

Revenue growth-1.7% · median 16.2%

Gross margin65.1% · median 78.4%

Net margin-3.4% · median 19.3%

Advertisement
300 × 250